Nephrocare Health Services Limited (BOM:544647)
India · Delayed Price · Currency is INR 734.00
+11.15 (1.54%)
At close: Jun 19, 2026
BOM:544647 Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, BOM:544647 stock has a consensus rating of "Buy" and an average price target of ₹771.25. The average 1-year stock price forecast is 5.07% higher than the current stock price, while the lowest is ₹660.00 (-10.08%) and the highest is ₹1,000 (+36.24%).
Price Target: ₹771.25 (+5.07%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BOM:544647 stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 2 |
| Buy | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 4 |
Financial Forecast
Revenue This Year
11.78B
from 9.99B
Increased by 17.92%
Revenue Next Year
13.87B
from 11.78B
Increased by 17.78%
EPS This Year
15.41
from 8.10
Increased by 90.25%
EPS Next Year
20.42
from 15.41
Increased by 32.48%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 12.0B | ||
| Avg | 11.8B | ||
| Low | 11.6B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 20.5% | ||
| Avg | 17.9% | ||
| Low | 16.2% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 15.41 | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | - | ||
| Avg | 90.2% | ||
| Low | - |